Targeted therapy in brain metastasis

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 679-686

  Soffietti, Riccardo ^a   Trevisan, Elisa ^a   Rudà, Roberta ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

brain metastases; breast cancer; lung cancer; melanoma; renal cancer; targeted agents

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CRIZOTINIB; DABRAFENIB; ERLOTINIB; GEFITINIB; INIPARIB; IPILIMUMAB; IRINOTECAN; LAPATINIB; OLAPARIB; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; VELIPARIB; VEMURAFENIB;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES;

EID: 84868205659     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283571a1c     Document Type: Review

References (104)

1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012; 14:48-54.
2. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multiinstitutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77:655-661.
3. Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 2012; 14:910-918.
4. Soffietti R, Rudà R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008; 20:676-684.
5. Eichler AF, Chung E, Kodack DP, et al. The biology of brain metastasestranslation to new therapies. Nat Rev Clin Oncol 2011; 8:344-356.
6. Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011; 21:107-112.
7. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012; 123:205-222.
8. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10:757-763.
9. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255-5261.
10. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16:269-278.
11. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from nonsmall cell lung cancer. J Neurooncol 2010; 100:443-447.
12. Patyna S, Peng J. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 2006; 4:21 (abstract).
13. Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117:501-509.
14. Lim ZD, Mahajan A, Weinberg J, et al. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol 2012
15. Novello S, Camps C, Grossi F, et al. Phase II study of sunitinib in patients with nonsmall cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011; 6:1260-1266.
16. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from nonsmall-cell lung cancer: a prospective trial. Ann Oncol 2004; 15:1042-1047.
17. Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced nonsmall-cell lung cancer. Lung Cancer 2004; 46:255-261.
18. Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from nonsmall-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004; 6:123-128.
19. Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from nonsmall cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47:129-138.
20. Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007; 57:359-364.
21. Lai CS, Boshoff C, Falzon M, et al. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 2006; 61:91 (abstract).
22. Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial metastases to erlotinib therapy. J Clin Oncol 2007; 25:5024-5026.
23. Popat S, Hughes S, Papadopoulos P, et al. Recurrent responses to nonsmall cell lung cancer brain metastases with erlotinib. Lung Cancer 2007; 56:135-137.
24. Altavilla G, Arrigo C, Santarpia MC, et al. Erlotinib therapy in a patient with nonsmall-cell lung cancer and brain metastases. J Neurooncol 2008; 90:31-33.
25. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37:624-631.
26. Bai H, Han B. The effectiveness of erlotinib against brain metastases in nonsmall-cell lung cancer patients. Am J Clin Oncol 2012 [Epub ahead of print].
27. Shimato S, Mitsudomi T, Kosaka T, et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 2006; 8:137-144.
28. Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009; 65:351-354.
29. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced nonsmall-cell lung cancer (NSCLC) patients with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006; 24:369s (abstract).
30. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010; 12:1193-1199.
31. Lind JS, Lagerwaard FJ, Smit EF, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from nonsmallcell lung cancer. Int J Radiat Oncol Biol Phys 2009; 74:1391-1396.
32. Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from nonsmall cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009; 65:198-203.
33. Pesce GA, Klingbiel D, Ribi K, et al. Outcome, quality of life and cognitive function of patients with brain metastases from nonsmall cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2012; 48:377-3784.
34. Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011; 67:1465-1469.
35. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
36. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29:e443-e445.
37. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271-3277.
38. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972-2977.
39. Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15:219-225.
40. Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45:196-201.
41. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13:1648-1655.
42. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009; 27:5278-5286.
43. Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17:4834-4843.
44. Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 2011; 6:e21030.
45. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011; 117:1837-1846.
46. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17:935-944.
47. Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67:4190-4198.
48. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18:23-28.
49. Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 2007; 20:864-870.
50. Dawood S, Gonzalez-Angulo AM, Albarracin C, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 2010; 116:3084-3092.
51. Le Scodan R, Jouanneau L, Massard C, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 2011; 11:395.
52. Xu Z, Marko NF, Chao ST, et al. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys 2012; 82:e739-e747.
53. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993-1999.
54. Lin NU, Dié ras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452-1459.
55. Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorization Temporaire d'Utilisation (ATU). J Clin Oncol 2008; 26:1094 (abstract).
56. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 2010; 102:995-1002.
57. Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22:625-630.
58. Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011; 105:613-620.
59. Bachelot TD, Romieu G, Campone M, et al. LANDSCAPE: an FNCLCC Phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 2011; 29:509 (abstract).
60. Lin NU, Ramakrishna N, Younger WJ, et al. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. J Clin Oncol 2010; 28:1154 (abstract).
61. Minami CA, Chung DU, Chang HR, et al. Management options in triplenegative breast cancer. Breast Cancer 2011; 5:175-199.
62. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-214.
63. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122:11-19.
64. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123:223-233.
65. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
66. Dummer R Jr, Goldinger SM, Wagner I, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 2011; 29:8548 (abstract).
67. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365:2439-2441.
68. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant BRAF kinase: evidence of activity in melanoma brain metastases (LBA27). Ann Oncol 2010; 21:viii12 (abstract).
69. Fong L, Small EJ. Anticytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26:5275-5283.
70. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830.
71. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
72. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
73. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-6688.
74. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008; 5:557-561.
75. Schartz NE, Farges C, Madelaine I, et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010; 20:247-250.
76. Weber JS, Amin A, Minor D, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21:530-534.
77. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
78. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010; 120:1368-1379.
79. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-1720.
80. Di Giacomo AM, Ascierto PA, Pittiglio E, et al. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma-the NIBIT M1 trial. Eur J Cancer 2011; 47:9305 (abstract).
81. Shapiro DG, Samlowski WE. Management of melanoma brain metastases in the era of targeted therapy. J Skin Cancer 2011; 2011:845-863.
82. Fisher R, Larkin J. Treatment of brain metastases in patients with melanoma. Lancet Oncol 2012; 13:434-435 (comment).
83. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011; 11:352-363.
84. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010; 16:5664-5678.
85. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 2012; 29:770-781.
86. Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010; 334:147-155.
87. Lagas J, van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010; 9:319-326.
88. Trinh VA, Hwu WJ. Chemoprevention for brain metastases. Curr Oncol Rep 2012; 14:63-69.
89. Kienast Y, von Baumgarten L, Fuhrmann M, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16:116-122.
90. Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010; 10:1763-1777.
91. Yin JJ, Zhang L, Munasinghe J, et al. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res 2010; 70:8662-8673.
92. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100:1092-1103.
93. Palmieri D, Lockman PR, Thomas FC, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009; 15:6148-6157.
94. Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 2011; 17:142-153.
95. Qian Y, Hua E, Bisht K, et al. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin Exp Metastasis 2010; 28:899-908.
96. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone inwomen with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-543.
97. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced nonsmall cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010; 16:5873-5882.
98. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116:1272-1280.
99. Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21:1027-1031.
100. Verma J, Jonasch E, Allen P, et al. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 2011; 117:4958-4965.
101. Peereboom DM. Clinical trial design in brain metastasis: approaches for a unique patient population. Curr Oncol Rep 2012; 14:91-96.
102. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for highgrade glioma: the evolving landscape. Neuro Oncol 2011; 13:353-361.
103. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol 2011; 29:606-609.
104. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963-1972.